← Back to Search

Bruton's Tyrosine Kinase (BTK) Inhibitor

Acalabrutinib + Rituximab and CAR T-Cell Therapy for Mantle Cell Lymphoma

Phase < 1
Recruiting
Led By Preetesh Jain, MD, PHD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 30 days after car t-cell infusion
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if a new combination of drugs can help control mantle cell lymphoma, a type of cancer.

Who is the study for?
This trial is for adults with newly diagnosed high-risk mantle cell lymphoma who haven't had treatment before. They must have specific genetic markers, be able to swallow pills, and have a good performance status (able to carry out daily activities). Women should not be pregnant and must use birth control. People can't join if they've had other cancers needing active treatment, certain heart or blood conditions, or are HIV positive.
What is being tested?
The study tests a combination of acalabrutinib and rituximab followed by brexucabtagene autoleucel therapy in patients with untreated high-risk mantle cell lymphoma. The goal is to see if this regimen controls the disease better than current treatments.
What are the potential side effects?
Possible side effects include nausea, diarrhea, headaches from acalabrutinib; infusion reactions like fever or chills from rituximab; and flu-like symptoms, low blood counts leading to infection risk or bleeding problems from brexucabtagene autoleucel.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 30 days after car t-cell infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 30 days after car t-cell infusion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events

Side effects data

From 2020 Phase 2 trial • 177 Patients • NCT04346199
2%
Headache
1%
Septic shock
1%
Ischaemic stroke
1%
Chronic obstructive pulmonary disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
BSC Alone
Acalabrutinib + BSC

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Brexucabtagene Autoleucel (Part 2)Experimental Treatment3 Interventions
Participants will have a procedure called leukapheresis to collect enough T cells.
Group II: Acalabrutinib and Rituximab (Part 1)Experimental Treatment4 Interventions
Participants may receive acalabrutinib and rituximab for up to 12 cycles. Each cycle is 28 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acalabrutinib
2020
Completed Phase 2
~2080
Rituximab
1999
Completed Phase 4
~2990
Cyclophosphamide
2010
Completed Phase 4
~2310
Fludarabine Phosphate
1997
Completed Phase 3
~2390

Find a Location

Who is running the clinical trial?

Acerta Pharma, LLCOTHER
6 Previous Clinical Trials
312 Total Patients Enrolled
Kite, A Gilead CompanyIndustry Sponsor
44 Previous Clinical Trials
3,960 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
3,066 Previous Clinical Trials
1,802,225 Total Patients Enrolled

Media Library

Acalabrutinib (Bruton's Tyrosine Kinase (BTK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05495464 — Phase < 1
Mantle Cell Lymphoma Research Study Groups: Acalabrutinib and Rituximab (Part 1), Brexucabtagene Autoleucel (Part 2)
Mantle Cell Lymphoma Clinical Trial 2023: Acalabrutinib Highlights & Side Effects. Trial Name: NCT05495464 — Phase < 1
Acalabrutinib (Bruton's Tyrosine Kinase (BTK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05495464 — Phase < 1
~11 spots leftby Mar 2027